GlassScriptPhysician profile
Sharnice Ragland
NPI 1255059812
$1,123.03
in general payments reported to CMS, 2019-2025
21 companies · $803 in 2025
The $803 reported for 2025 was more than what 81% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $45.24 · 2024: $274 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,023 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.04 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $173.27 | 2024-2025 | Veozah |
| Axsome Therapeutics, INC. | $108.37 | 2024-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $97.70 | 2025 | Airsupra, Breztri |
| Novo Nordisk INC | $92.22 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $79.09 | 2025 | |
| Neurocrine Biosciences, INC. | $69.55 | 2024-2025 | Ingrezza |
| Lilly USA, LLC | $64.58 | 2024-2025 | Zepbound, Kisunla, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $62.10 | 2024-2025 | Rexulti, Abilify Maintena |
| Novartis Pharmaceuticals Corporation | $59.63 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $54.29 | 2025 | Verquvo, Capvaxive |
| Exact Sciences Corporation | $42.45 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $40.33 | 2025 | |
| Xeris Pharmaceuticals, INC. | $37.49 | 2025 | Keveyis |
| Orexo US, INC. | $23.84 | 2024 | Zubsolv |
| Lundbeck LLC | $21.30 | 2025 | Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $17.93 | 2025 | Inspire |
| Ucb, INC. | $17.36 | 2025 | Nayzilam |
| Indivior INC. | $16.77 | 2024 | Sublocade |
| Aimmune Therapeutics, INC. | $15.60 | 2025 | Zenpep |
| Gilead Sciences, INC. | $14.74 | 2025 | |
| Baxter Healthcare | $14.42 | 2024 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharnice Ragland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.